CLAIMS

What is claimed is:

1. A pharmaceutical composition comprising a solid dispersion, wherein the solid dispersion comprises:

i) a compound of Formula (II) or a pharmaceutically acceptable salt thereof:



(II),

wherein G is hydrogen or -C(R_2R_2')-O-CO-O-R_3, in which each of R_2 and R_2', independently, is hydrogen or C_{1-4} alkyl; R_3 is C_{1-4} alkyl; the star (*) indicates a chiral center; and

ii) a pharmaceutically acceptable polymer,

wherein the pharmaceutically acceptable polymer is polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose acetate succinate (HPMCAS), or mixtures thereof,

wherein a weight ratio of the compound of Formula (II) or a pharmaceutically acceptable salt thereof to the pharmaceutically acceptable polymer is from 1:1 to 1:5, and

wherein the compound of Formula (II) or a pharmaceutically acceptable salt thereof is in a therapeutically effective amount from 5 mg to 200 mg.

2. The pharmaceutical composition according to claim 1, wherein the compound of Formula (II) is [1-((11*S*)-7,8-difluoro(6*H*,11*H*-dibenzo[*c*,*f*] thiepin-11-

yl))-4,6-dioxospiro[1,2,3,9-tetrahydropyridino[1,2-*e*]pyridazine-3,1'-cyclopropane]-5-yloxy]methyl methoxyformate, or 1'-((11*S*)-7,8-difluoro-6,11-dihydrodibenzo[*b,e*]thiepin-11-yl)-1',2'-dihydro-5'-hydroxy-spiro[cyclopropane-1,3'-(3*H*)pyrido[1,2-*b*]pyridazine-4',6'-dione.

3. The pharmaceutical composition according to claims 1, wherein the pharmaceutically acceptable polymer is Soluplus, HPC-SSL, HPMCAS-MG, HPMCAS-HG, or mixtures thereof.

4. The pharmaceutical composition according to claim 1, wherein the weight ratio of the compound of Formula (II) or a pharmaceutically acceptable salt thereof to the pharmaceutically acceptable polymer is from 1:1 to 1:3.

5. The pharmaceutical composition according to claim 1, wherein the compound of Formula (II) or a pharmaceutically acceptable salt thereof is in a therapeutically effective amount from 5 mg to 100 mg.

6. The pharmaceutical composition according to claim 1, wherein the solid dispersion is present at a concentration from 3% w/w to 40% w/w.

7. The pharmaceutical composition according to claim 1, wherein the solid dispersion has a D_{50} particle size in a range of 4 μm to 15 μm, or a D_{90} particle size in a range of 15 μm to 50 μm.

8. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition further comprises one or more fillers.

9. The pharmaceutical composition according to claims 8, wherein the pharmaceutical composition further comprises one or more binder and/or disintegrant.

10. The pharmaceutical composition according to claim 9, wherein the filler is selected from the group consisting of mannitol, microcrystalline cellulose, lactose, maltitol, dibasic calcium phosphate, sodium carboxymethycellulose, ethylcellulose, cellulose acetate, starch, glucose, fructose, sucrose, dicalcium phosphate, calcium

sulfate, cellulose, kaolin, sodium chloride, sorbitol, trehalose, mannitol, lactitol, xylitol, isomalt, erythritol, and hydrogenated starch hydrolysates, and a combination thereof; wherein the binder is selected from the group consisting of hydroxypropyl methylcellulose (HPMC), polyethylene glycol (PEG), polyvinylpyrrolidone-vinylacetate copolymer (PVP-VA), povidone, polyvinyl pyrrolidone (PVP), hydroxypropyl cellulose (HPC), methyl cellulose, and a combination thereof; and wherein the disintegrant is selected from the group consisting of croscarmellose, crospovidone, copovidone, microcrystalline cellulose, hydroxypropylmethyl cellulose, carboxymethyl starch, sodium starch glycolate, starch, carboxymethyl cellulose, alginate, and a combination thereof.

11. The pharmaceutical composition according to claim 10, wherein the filler is selected from the group consisting of D-mannitol, MCC 101, and a combination thereof; wherein the binder is selected from the group consisting of HPMC, HPC, PEG-4000, Povidone K30, PVP-VA64, and a combination thereof; and wherein the disintegrant is selected from the group consisting of croscarmellose sodium, crospovidone, Starch 1500, and a combination thereof.

12. The pharmaceutical composition according to claim 8, wherein the solid dispersion is present at a concentration from 3% w/w to 40% w/w, and wherein the filler is present at a concentration from 40% w/w to 95% w/w.

13. The pharmaceutical composition according to claim 9, wherein the solid dispersion is present at a concentration from 3% w/w to 40% w/w, the filler is present at a concentration from 40% w/w to 95% w/w, and the binder and/or disintegrant is present at a concentration from 1% w/w to 35% w/w.

14. The pharmaceutical composition according to claims 9, wherein the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients selected from the group consisting of diluents, lubricants,

glidants, surfactants, wetting agents, release rate modifiers, sweeteners, taste masking agents, colorants, and flavors.

15. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is in a dosage form selected from the group consisting of a granule, an oral disintegrating tablet (ODT), a suspension, a powder, a solution, a granule or a powder for reconstitution as a suspension or a solution, a syrup, an elixir, a dispersible/effervescent tablet, a chewable tablet, a troche, an oral thin strip, a sachet, a pellet, a pill, a capsule, a sprinkle oral powder, and an inhaler form.